Utilizing a histologically derived metric, TIL percentage, we were able to generate a predictive tool that could confidently screen for FGFR2/3 gene mutation, as well as other FGFR aberrations, in a large population of bladder cancer patients. This evidence concerns the gene FGFR2 and urinary bladder carcinoma.